Azithromycin

(UHZ-ith-row-MY-sin)

Trade Name(s):
Zithromax
  • Tablets
  • 250 mg (as dihydrate)
  • Tablets
  • 600 mg
  • Powder for injection
  • 500 mg
  • Powder for oral suspension
  • 100 mg/5 mL
  • Powder for oral suspension
  • 200 mg/5 mL
  • Powder for oral suspension
  • 1 g/packet

    Indicates Canadian trade names.

    Class:  AntibioticMacrolide

      Action:
    Interferes with microbial protein synthesis.

      Indications:

    Adults: Treatment of infections of the respiratory tract, chronic obstructive pulmonary disease (COPD), community acquired pneumonia, Mycobacterium avium complex, pelvic inflammatory disease, skin and skin structure, and sexually-transmitted diseases caused by susceptible organisms.

    Children: Treatment of acute otitis media caused by susceptible organisms; community-acquired pneumonia, treatment of pharyngitis/tonsillitis caused by Streptococcus pyogenes in patients who cannot use first-line therapy.

      Contraindications:
    Hypersensitivity to azithromycin, erythromycin, or to any macrolide antibiotic.

      Route/Dosage:

    Acute Otitis Media

    Children:
    PO 10 mg/kg as a single dose on the first day, not to exceed 500 mg/day. Then give 5 mg/kg on days 2 through 5, not to exceed 250 mg/day.

    Bacterial Infections

    Adults:
    PO 500 mg as single dose on first day, then 250 mg/day on days 2 through 5.

    Community Acquired Pneumonia

    Adults:
    PO 500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5.
    IV 500 mg as a single daily dose for 2 days. Follow IV therapy by the oral route at a single daily dose of 500 mg to complete 7- to 10-day course of therapy.

    Children 6 mo:
    PO 10 mg/kg as a single dose on the first day (not to exceed 500 mg/day), followed by 5 mg/kg on days 2 through 5 (not to exceed 250 mg/day).

    Gonorrhea

    Adults:
    PO Single 2 g dose.

    Mild to Moderate COPD

    Adults:
    PO 500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5.

    Mycobacterium Avium Complex

    Adults:
    PO 1.2 g taken once weekly.

    Pelvic Inflammatory Disease

    Adults:
    IV 500 mg as a single daily dose for 1 to 2 days. Follow IV therapy by the oral route at a single daily dose of 250 mg to complete a 7-day course of therapy.

    Pharyngitis/Tonsillitis

    Adults:
    PO 500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5.

    Children:
    PO 12 mg/kg/day for 5 days, not to exceed 500 mg/day.

    STDs

    Adults:
    PO Single 1 g dose.

    Uncomplicated Skin and Skin Structure Infections

    Adults:
    PO 500 mg as a single dose on the first day followed by 250 mg once daily for 4 days.

      Interactions:

    HMG-CoA reductase inhibitors (eg, lovastatin): Increased risk of myopathy and rhabdomyolysis.

    Tacrolimus: Increased tacrolimus plasma levels with increased risk of toxicity.

    Warfarin: The anticoagulant effect may be increased, increasing the risk of hemorrhage.

      Lab Test Interferences:
    None well documented.

      Adverse Reactions:

    CV:
    Palpitations; chest pain.
    CNS:
    Dizziness; headache; vertigo; somnolence; fatigue.
    DERM:
    Rash; photosensitivity.
    GI:
    Diarrhea; nausea; vomiting; abdominal pain; dyspepsia; flatulence; melena.
    GU:
    Vaginitis; monilia; nephritis.
    HEPA:
    Cholestatic jaundice.
    OTHER:
    Angioedema; anaphylaxis.

      Precautions:

    Pregnancy: Category B.

    Lactation: Undetermined.

    Cardiac effects: Serious cardiovascular events have occurred with other macrolide antibiotics, especially when given concomitantly with certain antihistamines (eg, terfenadine, astemizole).

    Gonorrhea/Syphilis: Ineffective for treatment of these infections.

    Hepatic/Renal impairment: Use cautiously.

    Pneumonia: Only effective for mild community-acquired pneumonia.

    Pseudomembranous colitis: May be factor in patients who develop diarrhea.


    Patient Care Considerations

      Administration/Storage:

    Oral Suspension

    Injection

      Assessment/Interventions:

      Patient/Family Education:


    AtoZ Drug Facts · Copyright©2000 by Facts and Comparisons